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Abstract
Friedreich ataxia (FRDA) is an autosomal recessive disorder characterized by neurodegeneration and cardiomyopathy. The
presence of a GAA trinucleotide repeat expansion in the first intron of the FXN gene results in the inhibition of gene
expression and an insufficiency of the mitochondrial protein frataxin. There is a correlation between expansion length, the
amount of residual frataxin and the severity of disease. As the coding sequence is unaltered, pharmacological up-regulation
of FXN expression may restore frataxin to therapeutic levels. To facilitate screening of compounds that modulate FXN
expression in a physiologically relevant manner, we established a cellular genomic reporter assay consisting of a stable
human cell line containing an FXN-EGFP fusion construct, in which the EGFP gene is fused in-frame with the entire normal
human FXN gene present on a BAC clone. The cell line was used to establish a fluorometric cellular assay for use in high
throughput screening (HTS) procedures. A small chemical library containing FDA-approved compounds and natural extracts
was screened and analyzed. Compound hits identified by HTS were further evaluated by flow cytometry in the cellular
genomic reporter assay. The effects on FXN mRNA and frataxin protein levels were measured in lymphoblast and fibroblast
cell lines derived from individuals with FRDA and in a humanized GAA repeat expansion mouse model of FRDA. Compounds
that were established to increase FXN gene expression and frataxin levels included several anti-cancer agents, the iron-
chelator deferiprone and the phytoalexin resveratrol.
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Introduction
Friedreich ataxia (FRDA) is an autosomal recessive disorder
characterized by neurodegeneration and cardiomyopathy. It is the
most common form of hereditary ataxia with an incidence of
approximately 1 in 50,000 in Caucasian populations [1]. About
98% of individuals with FRDA are homozygous for an expansion
of a GAA trinucleotide repeat sequence within the first intron of
the FXN gene. The remaining individuals are compound
heterozygotes for a GAA expansion and a point mutation, deletion
and/or insertion. Pathogenic GAA expansion alleles are in the size
range of 60 to more than 1300 repeats. The presence of a GAA
repeat expansion results in the inhibition of FXN gene expression,
reduced levels of full length FXN transcript and an insufficiency of
the mitochondrial protein frataxin [2–5].
Frataxin deficiency results in mitochondrial dysfunction includ-
ing the loss of iron-sulfur cluster (ISC)-containing enzymes,
increased oxidative damage and mitochondrial iron accumulation
[6–8]. Frataxin has been implicated to function as a multimeric
iron storage protein that also possesses ferroxidase activity [9], as
an iron chaperone which modulates mitochondrial aconitase
activity [10–12], as a mediator of iron delivery to ferrochelatase
[13] and in the early stages of ISC biogenesis by direct interaction
with ISU-type proteins [14–17]. The main sites of pathology
include the large sensory neurons of the dorsal root ganglia and
the dentate nucleus of the cerebellum [18,19].
The mechanism by which the GAA expansion results in
reduced FXN gene expression is not clear. There is evidence that
suggests that the GAA repeat expansion may form an unusual and
stable triple helical non-B DNA structure or DNA/RNA hybrid
that impedes transcription elongation [4,5,20]. It is now apparent
that the GAA repeat expansion generates a heterochromatin-
mediated gene silencing effect [21,22]. Changes in both DNA
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methylation and histone modification have been described [22–
28].
Overall, an inverse correlation has been found between the size
of the smaller GAA repeat expansion and transcript levels, the
amount of residual frataxin produced and the age of onset of
disease symptoms [29–33]. Heterozygous carriers of a GAA repeat
expansion produce about half the normal level of frataxin and are
asymptomatic. As the GAA repeat expansion mutation does not
alter the coding sequence of the gene, it is hypothesized that any
increase in frataxin levels should prove beneficial, while a several-
fold increase could be sufficient to halt disease progression.
We were the first group to propose the pharmacological up-
regulation of FXN gene expression as a novel therapeutic approach
for the treatment of FRDA [34]. Unlike pharmacological
treatments focused on secondary disease effects by using antiox-
idant and iron chelation therapy [35–37] our approach is aimed at
directly addressing the primary issue of frataxin deficiency.
We previously reported the identification of a 188 kb BAC
clone (RP11-265B8) containing exons 1–5b of the human FXN
locus and extensive flanking regions both upstream and down-
stream of the gene [34]. The clone contains a (GAA)6 sequence in
the region that undergoes expansion within the first intron of the
FXN gene. We demonstrated that the genomic insert is able to
successfully complement the embryonic lethal phenotype of
homozygous Fxn knockout mice, indicating that key regulatory
elements required for normal expression of the FXN gene are
present within this clone [38]. The BAC clone was used for the
generation of an FXN-EGFP genomic reporter construct in which
the EGFP gene was fused in-frame immediately following the final
codon of exon 5a of the human FXN gene [34]. The FXN-EGFP
genomic reporter preserves the normal location and spacing of
many regulatory elements that may be positioned over large
distances in the surrounding chromosomal region, and facilitates
the recapitulation of normal gene expression patterns [39]. The
construct was shown to drive the expression of EGFP from the
regulatory elements of the FXN locus in cell lines and transgenic
mice, with the frataxin-EGFP fusion protein targeted to the
mitochondria [34,40]. A stable BHK-21 cell line containing the
genomic reporter fusion was established and used to demonstrate
the induction of FXN gene expression by hemin and butyric acid
[34].
In this study we report the development of a stable human cell
line containing the FXN-EGFP genomic reporter fusion. The
sensitive cellular assay for FXN gene expression was used to
evaluate pharmacological agents for their ability to modulate FXN
gene expression and adapted for the high throughput screening
(HTS) of a small compound library. The evaluation of hit
compounds in cells from individuals with FRDA and in a
humanized GAA repeat expansion mouse model of FRDA
identified a number of agents that were able to increase FXN
gene expression and frataxin protein, including several anti-cancer
compounds, the iron-chelator deferiprone and the phytoalexin
resveratrol.
Materials and Methods
Ethics Statement
Lymphoblasts and fibroblasts from individuals with FRDA were
obtained from Coriell Cell Repositories (Camden, New Jersey,
USA) or collected following written informed consent with
approval from the Royal Children’s Hospital Human Research
Ethics Committee (project 22009). All procedures involving the
treatment of mice were carried out in accordance with the UK
Home Office ‘Animals (Scientific Procedures) Act 1986’ under
project license PPL70/6716. All efforts were made to minimize
suffering.
Tissue Culture and Transfection
HeLa and HeLa (FXN-EGFP) cell lines were maintained in
adherent culture in DMEM supplemented with 10% fetal calf
serum. Lymphoblasts were maintained in suspension culture in
RPMI 1640 supplemented with 20% fetal calf serum. Fibroblasts
were maintained in adherent culture in BME supplemented with
10% fetal calf serum. Media contained antibiotics (100 U/ml
penicillin and 0.1 mg/ml streptomycin) for routine cell mainte-
nance but were omitted during pharmacological compound
assays. Cells were cultured at 37uC in 5% CO2 atmosphere.
For transfection studies, HeLa cells were plated in 6-well culture
plates at a density of 26105 cells per well and allowed to reach 50–
80% confluency. Cells were transfected with 10 mg of purified
BAC DNA (linearized by digestion with AscI and BsiWI) using
LipofectAMINE (Life Technologies, Grand Island, NY, USA), at a
4:1 lipid to DNA ratio, according to the manufacturer’s protocol.
For the selection of stable clones, cells were transferred to 96-well
flat-bottom plates at two days post-transfection and grown in
medium containing 300 mg/ml G418 (Life Technologies). G418-
resistant clones were isolated via limiting cell dilution at 100–500
cells per ml. Cells were examined for EGFP expression by
fluorescence microscopy.
Fluorescence In Situ Hybridization (FISH) Analysis
Cell cultures were harvested after exposure to colcemid for 4
hours. Chromosome preparations were obtained using standard
techniques. Cells were spread onto slides and subsequently
denatured by immersion in 70% formamide in 26SSC at 73uC
for 3 minutes. The probe was prepared using purified DNA from
RP11-265B8, which was labeled by nick translation with
digoxigenin, according to the manufacturer’s instructions (Roche,
Mannheim, Germany). The labeled DNA was ethanol precipitated
together with human COT1 DNA and resuspended in 50%
formamide, 10% dextran sulfate, and 26SSC to a concentration
of 40 ng/ml. The probe was denatured by heating at 75uC for 8
minutes, followed by preannealing at 37uC for 20 minutes.
Hybridization was at 37uC for 16 hours followed by washing in
16SSC at 70uC for 5 minutes. The probe was detected with
mouse anti-digoxigenin antibody (Roche) followed by rhodamine
conjugated anti-mouse antibody (Rockland, Gilbertsville, PA,
USA). The slides were mounted in Vectashield (Vector Labora-
tories, Burlingame, CA, USA) containing DAPI counterstain.
Pharmacological Compound Analysis In Vitro
HeLa (FXN-EGFP) cells were plated at a density of 16104 cells
per ml, lymphoblasts were plated at a density of 16105 cells per ml
and fibroblasts were plated at a density of 56104 cells per ml in
appropriate media in 6-well culture plates. Cultures were
incubated overnight prior to removal of growth medium and
replacement with fresh medium containing various concentrations
of test compounds (Table 1). Cultures were incubated for a
further 72 hrs. Adherent cells were collected by trypsinization. All
cells were washed twice in phosphate-buffered saline (PBS). Assays
were performed on triplicate cultures in at least three independent
experiments.
Flow Cytometry
The proportion of EGFP-positive HeLa (FXN-EGFP) cells and
the relative levels of EGFP expression were measured by flow
cytometry. Cells were resuspended in PBS with 2% fetal calf
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PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e55940
serum. Flow cytometry was performed using a LSR II flow
cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA) and
analyzed using the FACSDiva Software Package.
Compound Library
The library screened was the Spectrum Collection (Micro-
Source Discovery Inc., Gaylordsville, CT, USA). The library
contains 2,000 biologically active and structurally diverse com-
pounds that are primarily Food and Drug Administration (FDA)-
approved compounds, bioactive compounds or natural products.
The compounds are supplied as 10 mM solutions in dimethyl
sulfoxide (DMSO). More details of the library can be found at
http://www.msdiscovery.com/spectrum.html.
High Throughput Screening Procedures
High throughput screening procedures were conducted at the
Walter and Eliza Hall Institute High-Throughput Chemical
Screening Facility (Bundoora, Victoria, Australia).
On Day 1 HeLa (FXN-EGFP) cells were seeded into 96-well
optical-grade NUNC Cytowell Special Optics microtiter plates
(Thermo Fisher Scientific, Rochester, NY, USA) at a density of
104 cells per well in a total volume of 200 ml of culture media
(DMEM supplemented with 10% fetal calf serum) using a
Multidrop 384 high-speed reagent dispenser (Thermo Electron
Corporation, Waltham, MA, USA). Cells were allowed to adhere
overnight at 37uC in 5% CO2 atmosphere.
On Day 2 each test compound was dispensed robotically from
the library into individual wells at a volume of 0.2 ml to achieve a
final concentration of 10 mM using a Zymark Mini Staccato
system (SOTAX Corporation, Westborough, MA, USA). Cultures
were incubated for a further 72 hours. Control rows and columns
were set up containing: media only, cells without any test
compounds, and cells exposed to the positive control drug cisplatin
(3.3 mM) which is known to increase FXN gene expression. In
addition, parental HeLa cells not containing the FXN-EGFP
genomic reporter were set up as a measure of background cell
fluorescence.
On Day 5 the cells were washed twice with 200 ml of PBS via a
MiniTrak IX automated liquid handling system (PerkinElmer,
Waltham, MA, USA) and overlaid with 200 ml of PBS prior to the
fluorometric measurement of EGFP levels in an Envision 2100
Multilabel plate reader (PerkinElmer) configured for EGFP
bottom-plate measurements at multiple locations per well.
Cell Viability Assay
To correct for variations in cell number from well to well due to
possible toxicity of different test compounds a measurement of cell
viability was performed. This was done following measurement of
EGFP levels using the CellTiter-Blue cell viability assay (Promega,
Table 1. Properties of selected compounds.
Compound CAS number Molecular formula Molecular weight Suppliera
d-Aminolevulinic acid 106-60-5 C5H9NO3 131.13 Sigma Aldrich
Ascorbic acid 50-81-7 C6H8O6 176.12 Sigma Aldrich
Benzalkonium chloride 8001-54-5 C22H40ClN 354.02 Sigma Aldrich
Betamethasone 378-44-9 C22H29FO5 392.46 Sigma Aldrich
Bupropion hydrochloride 34841-39-9 C13H18ClNO 239.74 Sigma Aldrich
Camptothecin 7689-03-4 C20H16N2O4 348.35 Sigma Aldrich
Cefdinir 91832-40-5 C14H13N5O5S2 395.42 Sigma Aldrich
Chlorpropham 101-21-3 C10H12ClNO2 213.67 Sigma Aldrich
Chrysanthemic acid 4638-92-0 C10H16O2 168.23 Sigma Aldrich
Cisplatin 15663-27-1 H6Cl2N2Pt 301.1 Mayne Pharma
Clozapine 5786-21-0 C18H19ClN4 326.82 Sigma Aldrich
Convallatoxin 508-75-8 C29H42O10 550.65 Sigma Aldrich
Deferiprone 30652-11-0 C7H9NO2 139.15 Lipomed
Desferrioxamine 70-51-9 C25H48N6O8 560.68 Novartis
Dimethyl sulfoxide 67-68-5 C2H6OS 78.13 Sigma Aldrich
Ethanol 64-17-5 C2H6O 46.07 Merck
Ferric ammonium sulfate 10138-04-2 FeNH4(SO4)2 266.07 Sigma Aldrich
Ferrous ammonium sulfate 10045-89-3 (NH4)2Fe(SO4)2 284.05 Sigma Aldrich
Hemin 16009-13-5 C34H32ClFeN4O4 651.94 Sigma Aldrich
Molsidomine 25717-80-0 C9H14N4O4 242.24 Sigma Aldrich
Nimustine 42471-28-3 C9H13ClN6O2 272.70 Sigma Aldrich
Phenothrin 26002-80-2 C23H26O3 350.46 Sigma Aldrich
Resveratrol 501-36-0 C14H12O3 228.24 Sigma Aldrich
Rifampin 13292-46-1 C43H58N4O12 822.96 Sigma Aldrich
Sulfameter 651-06-9 C11H12N4O3S 280.30 Sigma Aldrich
aLipomed (Arlesheim, Switzerland), Mayne Pharma (Indianapolis, IN, USA), Merck (Darmstadt, Germany), Novartis (East Hanover, NJ, USA), Sigma Aldrich (St. Louis, MO,
USA).
doi:10.1371/journal.pone.0055940.t001
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Alexandria, NSW, Australia). Culture medium containing the
CellTiter-Blue reagent (resazurin) was added to each well and
plates incubated at 37uC for 90 minutes. The signal produced by
conversion of resazurin to resorufin is directly proportional to
viable cell number and was detected fluorometrically in an
Envision 2100 plate reader set up for top-plate measurements. A
standard curve of cell number versus viability was established for
each run.
Post High Throughput Screening Data Analysis
All fluorescence readings were exported into a set of Microsoft
Excel spread sheets programmed to perform the necessary data
analysis. The viability readings were converted to cell numbers for
each well using the standard curve described above. The average
background fluorescence of parental HeLa cells was subtracted
from the EGFP readings of HeLa (FXN-EGFP) cell exposed to the
chemical library. A correction factor for the number of viable cells
was applied to the EGFP levels in each corresponding well. This
was compared to the average value obtained from cells not
exposed to any test compound to determine the level of change in
FXN gene expression (represented as fold change in expression).
This is represented as:
Relative expression~
(EGFP fluorescence per treated well
{background)=(Cell viability of treated cells)
(EGFP fluorescence per treated well
{background)=(Cell viability of untreated cells)
:
Pharmacological Compound Analysis In Vivo
The YG8R FRDA mice [41] were housed in conventional open
cages with Litaspen Premium 8/20 bedding, paper wool nesting
and standard fun tunnel environmental enrichment, with 13 hours
light, 11 hours dark, 20–23uC and 45–60% humidity. The mice
were given a diet of SDS RM3 Expanded food pellets and
standard drinking water. YG8R mice at an age of 9–12 months
were given subcutaneous injections for three consecutive days of
25–300 mg/kg resveratrol in a vehicle solution of 6.25% DMSO,
20% glycerol, 20% PEG400, 20% propylene glycol, 5 mM sodium
acetate (pH 5.2). Each dose of resveratrol or vehicle was evaluated
in four mice. After either four hours or 24 hours mice were culled
and tissues were collected and snap frozen in liquid nitrogen.
Quantitative Real-time Reverse Transcription PCR
Total cellular mRNA was isolated from cultured cell lines using
the Dynabeads mRNA DIRECT Kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Reverse
transcription was performed using the SuperScript II First Strand
Synthesis System (Invitrogen) with oligo (dT)12–15 primers. Real-
time PCR was performed on an ABI7300 Sequence Detection
System (Applied Biosystems, Carlsbad, CA, USA) using TaqMan
Gene Expression Assays (Applied Biosystems) with primers and
probes specific for the human FXN gene (Hs00175940_m1) and
human hypoxanthine phosphoribosyltransferase 1 (HPRT1)
(Hs99999909_m1) as the reference gene. FXN gene expression
was determined using the comparative Ct method (DDCt) relative
to the endogenous control HPRT1. Assays were performed in
triplicate in at least three independent experiments.
Total RNA was isolated from snap frozen YG8R mouse brain
tissues by homogenization with Trizol (Invitrogen) and cDNA was
prepared by using AMV reverse transcriptase (Invitrogen) with
oligo-dT primers. Levels of human transgenic FXN expression
were assessed by quantitative RT-PCR using an ABI7900
sequencer and SYBR Green (Applied Biosystems) with the primers
FRT-I (59-TTGAAGACCTTGCAGACAAG-39) and RRT-II
(59-AGCCAGATTTGCTTGTTTGG-39). Mouse Gapdh RT-
PCR primers used for normalization were GapdhmF (59-
ACCCAGAAGACTGTGGATGG-39) and GapdhmR (59-
GGATGCAGGGATGATGTTCT-39).
Frataxin Protein Measurements
The levels of frataxin protein were measured by lateral flow
immunoassay with the Frataxin Protein Quantity Dipstick Assay
Kit (MitoSciences, Eugene, Oregon, USA) according to the
manufacturer’s instructions [42]. Signal intensity was measured
with a Hamamatsu ICA-1000 Immunochromatographic Reader
(MitoSciences).
Statistical Analyses
For the evaluation of pharmacological compounds in cell lines,
the experimental data is reported as the mean 6 the standard
error of the mean (SEM) of triplicate assays in at least three
independent experiments. Comparisons were made between
groups of equal size by Student’s t-test for paired data. For the
evaluation of pharmacological compounds in mice, reactions were
carried out in triplicate for each biological sample (n = 4) and data
from the vehicle and drug-treated groups were compared using the
Student’s t-test. Data were considered significantly different at
p,0.05.
Results
Generation and Characterization of HeLa (FXN-EGFP)
Stable Cell Lines
We previously generated an FXN-EGFP genomic reporter fusion
by using homologous recombination [43] to insert an EGFP-Kan/
Neo cassette in-frame immediately following the final codon of
exon 5a of the normal human FXN gene present on the 188 kb
BAC clone RP11-265B8 [34]. The modified genomic insert from
the BAC clone (Figure 1A) was isolated from most of the vector
sequence by digestion at unique sites with AscI and BsiWI and
transfected into HeLa cells. A number of stable cell lines were
produced and selected for the Kan/Neo resistance determinant
using G418, followed by limiting dilution to establish single cell
clones (Figure 1B). Examination of a number of independent
stable clones by flow cytometry indicated that the proportion of
EGFP-positive cells in each clone was greater than 96%. These
clones exhibited a tight fluorescence peak, indicating high
homogeneity of the cell population, and varying values of median
peak fluorescence (data not shown). The proportion of EGFP-
positive cells and the relative levels of EGFP expression were found
to be stable following growth in continuous culture for over 90
days (25 passages) (Figure 1C). Fluorescent in situ hybridization
(FISH) using the entire RP11-265B8 sequence as a probe was
performed on metaphase spreads of a selected HeLa (FXN-EGFP)
stable cell line. HeLa cells have altered ploidy and three
hybridization signals were observed corresponding to the endog-
enous FXN gene. The stable clone displayed an additional and
brighter hybridization signal establishing the presence of a single
integration site containing multiple copies of the FXN-EGFP
transgene (Figure 1D).
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Primary Compound Screening Procedures
A small-scale non-automated primary screen was conducted in
which selected compounds were evaluated over a 10,000-fold
concentration range on HeLa (FXN-EGFP) cells and EGFP
fluorescence was measured by flow cytometry. Compounds were
selected based on the known pathophysiology of FRDA including
those involved in iron metabolism and antioxidants. Compounds
were dissolved in water, ethanol or dimethyl sulfoxide (DMSO), as
appropriate. None of the solvents had a significant effect on cell
viability or the expression of the FXN-EGFP reporter at the
concentrations used in the cellular assay (Figure 2). The anti-
cancer compound cisplatin (3.3 mM) elicited a 2.2-fold increase in
FXN-EGFP expression. The iron-chelator deferiprone (100 mM)
was found to increase expression by 1.6-fold and the phytoalexin
resveratrol (25 mM) increased expression by 1.7-fold. The combi-
nation of any two of these three compounds did not result in an
additive effect on FXN-EGFP expression (data not shown). The
other compounds tested had no notable effect on the level of FXN-
EGFP expression.
High Throughput Screening Procedures
The HeLa (FXN-EGFP) cellular genomic reporter assay was
adapted for use in high throughput screening procedures. Cells
were cultured in 96-well optical-quality microtiter plates and
measurement of EGFP levels was via a fluorometer. To correct for
well to well variations in cell number a measurement of cell
viability was incorporated. HTS procedures were undertaken at
the Walter and Eliza Hall Institute High-Throughput Chemical
Screening Facility. The Spectrum Collection was screened which
is a library containing 2,000 biologically active and structurally
diverse compounds that are primarily FDA-approved compounds
and some natural products. Each test compound was evaluated at
a final concentration of 10 mM. Fluorometric measurement of
EGFP fluorescence was performed using a bottom-plate reader
followed by cell viability assays. A standard curve of cell number
versus viability was also established for each run. The average
background fluorescence of parental HeLa cells was subtracted
from the EGFP readings of HeLa (FXN-EGFP) cells exposed to the
chemical library. A correction factor for the number of viable cells
was applied to the EGFP levels in each corresponding well. This
was compared to the average value obtained from cells not
Figure 1. Characterization of HeLa (FXN-EGFP) stable cell lines. (A) Diagrammatic representation of the BAC genomic DNA fragment
containing the FXN-EGFP genomic reporter construct. The sequence includes exons 13–16 of the PIP5K1B gene and the PRKACG gene upstream of the
FXN locus, and about 23 kb of additional sequence downstream of exon 5b. The exon 5a–EGFP–Kan/Neo region is shown in greater detail. (B)
Microscopic imaging. Transmitted light (left) and fluorescence (right) images of a HeLa (FXN-EGFP) stable cell line. EGFP expression produced by the
FXN-EGFP genomic reporter is evident in all cells. (C) Flow cytometric analysis. The levels of EGFP expression (left Y-axis) and the proportion of EGFP-
positive cells (right Y-axis) were stable following growth in continuous culture. (D) Determination of transgenic fragment integration site by FISH.
Rhodamine-labeled RP11-265B8 was hybridized onto metaphase chromosomes (DAPI stained) of HeLa (left) and HeLa (FXN-EGFP) (right) cells. Three
hybridization signals (yellow arrows) corresponded to the endogenous FXN gene. The presence of one additional brighter signal (orange arrow)
establishes the presence of a single integration site containing multiple copies of the FXN-EGFP transgene.
doi:10.1371/journal.pone.0055940.g001
Figure 2. Primary compound screen. The HeLa (FXN-EGFP) stable cell line was exposed to various concentrations of selected test compounds for
72 hours. The levels of EGFP expression were measured by flow cytometry. For each compound the lowest concentration that produced the greatest
change in FXN-EGFP expression is shown. Assays were performed in triplicate on at least three independent occasions. Error bars represent standard
error of the mean. **p,0.01 in comparison to the untreated control.
doi:10.1371/journal.pone.0055940.g002
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exposed to any test compound to determine the level of change in
FXN gene expression.
Following the complete screening of the 2,000 compound
library, 18 hit compounds were identified that elicited a greater
than three-fold increase in FXN-EGFP expression at a concentra-
tion of 10 mM in the HeLa (FXN-EGFP) genomic reporter assay
(Figure 3). A total of 74 compounds were identified that elicited a
greater than 1.5-fold increase in EGFP expression (30 compounds
increased expression by 1.5–2-fold; 15 by 2–2.5-fold; and 11 by
2.5–3-fold).
Most of the primary hit compounds that increased expression by
greater than 1.5-fold that were available for commercial purchase
or closely related analogs that were available were subjected to
dose-response experiments over a large concentration range on
HeLa (FXN-EGFP) cells and EGFP fluorescence was measured by
flow cytometry. Three compounds were validated to reproducibly
increase EGFP levels by greater than 1.5-fold in the flow
cytometric analysis (Figure 4). The greatest level of induction
was observed with the anti-cancer compound camptothecin,
which elicited a 3.3-fold increase in FXN-EGFP expression at a
concentration of 20 nM. This is the greatest level of induction that
we have observed with the HeLa (FXN-EGFP) genomic reporter
assay. The glucocorticoid betamethasone (6 mM) and the alkylat-
ing agent nimustine (10 mM) increased FXN-EGFP expression by
1.5-fold and 1.7-fold, respectively. Bupropion hydrochloride
(100 mM), chrysanthemic acid (100 mM), convallatoxin (10 mM),
molsidomine (10 mM) and sulfameter (100 mM) elicited modest
(less than 1.5-fold) but significant levels of induction of FXN-EGFP
expression.
Compound Evaluation in Friedreich Ataxia Cells
The FXN-EGFP genomic reporter contains a normal copy of the
FXN gene without a GAA trinucleotide repeat expansion. Selected
compounds were therefore subsequently evaluated on cells derived
from individuals with FRDA. Transformed lymphoblasts and
primary fibroblasts containing a GAA trinucleotide expansion on
both FXN alleles were used. The levels of FXN mRNA were
measured by quantitative real time RT-PCR and the levels of
frataxin protein were measured by lateral flow immunoassay
(dipstick assay).
The anti-cancer compounds cisplatin (3.3 mM) and camptothe-
cin (20 nM) were found to increase the level of FXN mRNA by
over 2-fold in FRDA lymphoblasts. Resveratrol (25 mM) increased
mRNA levels by 2-fold in FRDA lymphoblasts. Betamethasone
(6 mM), deferiprone (100 mM) and molsidomine (10 mM) elicited
increases in the level of FXN mRNA by over 1.5-fold in FRDA
lymphoblasts (Figure 5A). Cisplatin (13.2 mM) and deferiprone
(100 mM) were found to increase the level of FXN mRNA by over
1.5-fold in FRDA fibroblasts. Resveratrol (100 mM) elicited a 2.4-
fold increase in FXN mRNA levels in FRDA fibroblasts
(Figure 5B).
Cisplatin (3.3 mM) was found to increase the levels of frataxin
protein by 2.2-fold in FRDA lymphoblasts. Deferiprone (100 mM),
nimustine (10 mM) and resveratrol (25 mM) each increased the
levels of frataxin protein by1.7-fold in FRDA lymphoblasts.
Betamethasone (6 mM) elicited a 1.4-fold increase in frataxin
levels in FRDA lymphoblasts (Figure 5C). Cisplatin (3.3 mM),
deferiprone (100 mM) and resveratrol (25 mM) increased frataxin
Figure 3. High throughput screening. The HeLa (FXN-EGFP) stable cell line was used in high throughput screening procedures to screen the
Spectrum Collection compound library. Each test compound was evaluated at a final concentration of 10 mM. Controls included untreated cells and
cells exposed to 3.3 mM cisplatin. Cultures were incubated for 72 hours. The fluorometric measurement of EGFP fluorescence was performed followed
by the fluorometric measurement of cell viability. The average background fluorescence of parental HeLa cells was subtracted from the EGFP
readings of HeLa (FXN-EGFP) cells exposed to the chemical library. A correction factor for the number of viable cells was applied to the EGFP levels in
each corresponding well. This was compared to the average value obtained from cells not exposed to any test compound to determine the level of
change in FXN gene expression.
doi:10.1371/journal.pone.0055940.g003
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protein levels by 2.4-fold, 1.6-fold and 2-fold, respectively, in
FRDA fibroblasts (Figure 5D).
Compound Evaluation in a Friedreich Ataxia Mouse
Model
As resveratrol is a safe drug and has a number of proposed
modes of action that may be beneficial in FRDA including
neuroprotection, cardioprotection and antioxidant properties, an
in vivo evaluation of this compound was conducted in a YAC-based
GAA expansion humanized mouse model of FRDA [44]. The
YG8R transgenic mice contain the entire human genomic FXN
gene containing a GAA repeat expansion in the first intron of the
gene, and also contain a homozygous knockout of the murine Fxn
gene. Only transgenic human frataxin protein is expressed in the
mice. The mice provide the same underlying molecular cause of
the disease as found in individuals with FRDA and exhibit
decreased frataxin levels, progressive neuronal and cardiac
pathology that recapitulates that seen in individuals with FRDA
and measurable neurobehavioral deficits consistent with that
observed in FRDA [41].
Resveratrol was administered daily for three days by subcuta-
neous injection at doses ranging from 25–300 mg/kg. Samples
were collected at four and 24 hours after the final dose. The levels
of human FXN mRNA were measured by real-time RT-PCR. An
increase in human FXN gene expression of almost 2-fold was
observed in mouse brain at a dose of 200 mg/kg (Figure 6A). The
levels of human frataxin protein were measured by lateral flow
immunoassay. Human frataxin protein was found to increase by
1.5-fold in transgenic mouse brain at the same dose (Figure 6B),
indicating the ability of resveratrol to cross the blood-brain barrier
and to exert a frataxin-inducing effect. Interestingly, no other dose
of resveratrol resulted in an increase in FXN mRNA or frataxin
protein levels in mice and some doses resulted in a reduction in
mRNA.
Discussion
The clinical manifestations of FRDA are due to the presence
of a GAA trinucleotide repeat expansion within the first intron
of the FXN gene that results in decreased gene expression and
an insufficiency of frataxin protein. An overall inverse correla-
tion exists between the length of the smaller GAA repeat
expansion and the level of FXN transcript, the amount of
frataxin protein and the age of onset of disease symptoms [29–
33]. Individuals who are heterozygous for a GAA repeat
expansion produce about half the normal level of frataxin and
are asymptomatic. The GAA repeat expansion mutation does
not alter the coding sequence of the gene and the low levels of
frataxin protein produced retain normal function. In theory, any
increase in frataxin levels should prove beneficial, while a
Figure 4. High throughput screening compound validation. The HeLa (FXN-EGFP) stable cell line was exposed to various concentrations of
compounds identified by high throughput screening. Cultures were incubated for 72 hours. The levels of EGFP expression were measured by flow
cytometry. For each compound the lowest concentration that produced the greatest change in FXN-EGFP expression is shown. Assays were
performed in triplicate on at least three independent occasions. Error bars represent standard error of the mean. *p,0.05, **p,0.01 in comparison to
the untreated control.
doi:10.1371/journal.pone.0055940.g004
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several-fold increase could be sufficient to halt disease progres-
sion. Initiation of treatment at the onset of symptoms or prior
to onset has the potential to delay or prevent the manifestation
of disease pathology. The pharmacological up-regulation of FXN
gene expression is a therapeutic approach for the treatment of
FRDA that directly addresses the primary issue of frataxin
deficiency rather than secondary disease effects.
In order to rapidly and accurately monitor human FXN gene
expression and evaluate compounds for their ability to modulate
the expression of the gene, we developed an FXN-EGFP genomic
Figure 5. Compound evaluation in Friedreich ataxia cells. The modulation of FXN gene expression by selected test compounds was evaluated
in lymphoblast and fibroblast cell lines derived from individuals with FRDA. All cell lines were homozygous for a GAA repeat expansion in the first
intron of the FXN gene. Cultures were incubated for 72 hours. FXN mRNA levels were measured by real-time RT-PCR. Frataxin protein levels were
measured by lateral flow immunoassay. (A) FXN mRNA levels measured in FRDA lymphoblast cell lines. (B) FXN mRNA levels measured in FRDA
fibroblast cell lines. (C) Frataxin protein levels measured in FRDA lymphoblast cell lines. (D) Frataxin protein levels measured in FRDA fibroblast cell
lines. Assays were performed in triplicate on at least three independent occasions. Error bars represent standard error of the mean. *p,0.05,
**p,0.01 in comparison to the untreated control.
doi:10.1371/journal.pone.0055940.g005
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reporter that consists of the fusion of the EGFP gene in-frame
immediately following the final codon of exon 5a of the normal
human FXN gene present on a BAC clone [34]. Genomic
reporters preserve the normal location and spacing of many
regulatory elements that may be positioned over large distances in
the surrounding chromosomal region and more accurately
recapitulate expression patterns of tagged genes than can be
obtained with conventional small vector transgenic constructs. We
have now developed a cellular genomic reporter assay for FXN
gene expression by the generation of a stable HeLa cell line
containing the FXN-EGFP genomic reporter that permits the
precise measurement of human FXN gene expression by flow
cytometry and fluorometry.
The FXN-EGFP reporter construct could be stably maintained
and expressed in HeLa cells. We did not observe reduced cell
viability, reduction in fluorescence or variegation of expression in
the stable cell line after repeated passages of cell cultures. The
HeLa cell line was selected because a robust and rapidly growing
human cell type with undemanding growth conditions was
required for HTS procedures. As the FXN gene appears to be
expressed in all cell types analyzed we did not believe that it was
necessary to introduce the FXN-EGFP genomic reporter into cell
lines derived from tissues affected in the disorder, namely neuronal
and cardiac cells. In addition, the more fastidious growth
requirements of such cell types would negatively impact on the
feasibility of HTS procedures.
EGFP expression in the cellular assay is under the control of the
natural FXN promoter and regulatory elements present on the
BAC clone. As the FXN gene is not highly expressed the levels of
EGFP expressed by the FXN-EGFP genomic reporter were
relatively low. EGFP expression was sufficiently robust for
accurate and reproducible measurement by flow cytometry but
required careful optimization of the fluorometric detection system
used in HTS procedures. The specific HeLa (FXN-EGFP) stable
cell line that was selected for compound screening procedures
produced the highest levels of mean peak fluorescence among the
clones isolated and was shown by FISH analysis to contain
multiple copies of the FXN-EGFP transgene at a single integration
site. This clone was used in order to maximize the signal-to-noise
ratio.
An advantage of using EGFP as a readout of gene expression is
that EGFP reporter expression can be visualized in living cells
without the need for cell fixation, cell disruption or addition of
enzymatic substrates. For flow cytometry purposes, cells are
collected and readings are made on a per cell basis. For HTS
procedures the detection of EGFP fluorescence can be made in situ,
but HeLa cells and derivatives grow as a monolayer attached to
the bottom of culture vessels and the EGFP signal is not uniformly
distributed in solution throughout each well. It was therefore
necessary to adapt the optics of the plate reader to make
measurements from beneath the growth chamber focused on a
plane corresponding to the cell monolayer. Optical-grade micro-
titer plates were necessary in order to minimize quenching of the
signal read through the base of the plates. In order to account for
the possible non-uniform growth of cells exposed to certain
compounds, readings were taken at multiple positions for each
well. To increase the signal-to-noise ratio in future screens the
assay system could be modified to express an alternative reporter
with greater signal intensity or by using a two-step transcriptional
amplification (TSTA) system [45] to amplify the signal.
Changes in frataxin-EGFP content per cell in response to
exposure to pharmacological compounds may reflect not only
changes at the transcriptional level, but also changes in the
processing and export of mRNA and in mRNA and protein
turnover. This is a significant advantage of the FXN-EGFP assay
system, since changes in any one of these processes could affect
frataxin levels in a therapeutic manner. It is possible that the
induction of frataxin expression quantified by the FXN-EGFP
cellular genomic reporter assay may be underestimated due to
turnover of the fusion protein during the induction period. EGFP
has been reported to have a half-life of about 26 hours [46] but the
Figure 6. Evaluation of resveratrol in a Friedreich ataxia mouse
model. The modulation of FXN gene expression by resveratrol was
evaluated in the YG8R humanized FRDA mouse model. Resveratrol was
administered daily for three days by subcutaneous injection. (A) The
levels of human FXN mRNA were measured by real-time RT-PCR. Brain
samples were collected at four and 24 hours after the final dose. (B) The
levels of human frataxin protein were measured by lateral flow
immunoassay. Brain samples were collected four hours after the final
dose. Reactions were carried out in triplicate for each biological sample
(n = 4). Error bars represent standard error of the mean. *p,0.05,
**p,0.01, ***p,0.001 in comparison to the untreated control (vehicle).
doi:10.1371/journal.pone.0055940.g006
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half-life of the frataxin-EGFP fusion protein has not been
determined. Cells are typically incubated with test compounds
for a period of 72 hours in the assay system. The effects of
compounds with a short half-life may be diminished at the time of
readout. Some of these issues could be alleviated by replenishing
cultures with fresh test compound periodically throughout the
assay incubation period or taking more frequent readings.
However, these modifications would increase the complexity and
costs of HTS procedures.
The level of increase in EGFP expression induced by the
positive control drug cisplatin quantified via fluorometric mea-
surement in the HTS assay (1.4-fold) was lower than that
measured via flow cytometry (2.2-fold). This likely represents
inherent differences in the quantification of fluorescence by the
two detection techniques and could contribute to false negative
readouts. Other factors leading to potential false negative results
include compounds causing complete cell death at the tested
concentration (10 mM) or those not sufficiently potent at this
concentration. False positive readouts could be attributed to
compounds that were intrinsically fluorescent or to stochastic
variability inherent in the HTS assay that was performed a single
time. Post-HTS verification evaluation identified false positive
compounds and excluded them from further consideration.
The entire 2,000 compound Spectrum Collection library was
subjected to HTS procedures. The relatively small size of the
chemical library made it cost-effective and suitable for use as an
initial proof-of-principle screen. In addition, as the majority of the
compounds in this library are FDA-approved, it was envisaged
that promising hit compounds could be more rapidly moved into a
clinical setting. The screening of such a library also lends itself to
the Selective Optimization of Side Activities (SOSA) approach in
which known pharmacological agents are structurally modified to
give increased affinity for a new target [47].
Of therapeutic relevance, it is important to underscore that
although the FXN-EGFP genomic reporter contains a normal copy
of the FXN gene without a GAA trinucleotide repeat expansion, its
use has allowed the identification of a number of agents that are
capable of increasing FXN gene expression and frataxin protein in
FRDA cells. However, classes of compounds that are specifically
able to overcome the effects of the GAA repeat expansion on FXN
gene expression would not be detected using this assay. This
limitation could be overcome by the development of an FXN
genomic reporter construct containing a long GAA repeat
expansion.
Two anticancer agents, cisplatin and camptothecin, were found
to elicit the highest levels of induction in the HeLa (FXN-EGFP)
genomic reporter and in FRDA lymphoblasts and fibroblasts.
Cisplatin is a platinum-containing compound that binds to and
cross-links DNA most commonly acting at adjacent guanine
residues [48]. It was previously shown to increase FXN gene
expression in a cisplatin-resistant ovarian carcinoma cell line [49].
Camptothecin is a cytotoxic quinoline alkaloid that inhibits DNA
topoisomerase I [50]. The mechanisms of action that modulate
FXN gene expression are not known but likely due to non-specific
effects. Both drugs have toxic side-effects that limit their use for the
long-term treatment of FRDA.
Deferiprone is a membrane-permeable iron-chelator that has
the ability to shuttle iron between cellular organelles and across
membranes [51]. Deferiprone binds to ferric ions to form neutral
3:1 (deferiprone:iron) complexes. It is in clinical use for the
treatment of thalassemia. In an open-label clinical trial examining
individuals with FRDA deferiprone appeared to reduce accumu-
lated iron in the dentate nucleus and reduced neuropathy and
ataxic gait [35]. Our findings indicate that deferiprone is also able
to induce FXN gene expression and increase the levels of frataxin
suggesting that intracellular iron levels can modulate FXN gene
regulation. Besides the direct effects of deferiprone on iron
mobilization in FRDA it may confer the additional benefit of
increased frataxin levels.
A number of compounds were found to elicit modest but
measurably reproducible increases in FXN-EGFP expression.
These include: bupropion, a norepinephrine-dopamine reuptake
inhibitor used as an antidepressant; chrysanthemic acid, a
compound related to pyrethroids; onvallatoxin, a glycoside used
in the treatment of cardiac conditions; and sulfameter, a long-
acting sulfonamide antibacterial. Additional compounds that were
identified to result in small increases in FXN gene expression and
frataxin protein in FRDA cells include: betamethasone, a
glucocorticoid with anti-inflammatory and immunosuppressive
properties; nimustine, a nitrosourea alkylating agent with anti-
neoplastic activity; and molsidomine, an orally active and long
acting vasodilating drug.
Resveratrol was identified in the HeLa (FXN-EGFP) cellular
genomic reporter to increase FXN gene expression by 1.7-fold. It
was subsequently shown to increase FXNmRNA levels by 2-fold in
FRDA lymphoblasts and by 2.4-fold in FRDA fibroblasts. It
elicited an increase in frataxin protein by 1.7-fold in FRDA
lymphoblasts and by 2-fold in FRDA fibroblasts. Resveratrol
(3,49,5-trihydroxy-trans-stilbene) is a polyphenolic compound that
is synthesized naturally by several plant species. It is commonly
found in red grape skin, berries and nuts [52]. Resveratrol is a
phytoalexin; a toxic compound produced by higher plants in
response to infection or other stresses. Resveratrol appears to have
a wide spectrum of targets as a pharmacological agent. It has been
proposed as a treatment for cancers, cardiac disease, neurodegen-
erative conditions and metabolic disorders including diabetes
[53,54]. It has also been reported to possess antioxidant, anti-
inflammatory, anti-angiogenic and antiviral properties. There is
evidence that resveratrol contributes to enhanced longevity in S.
cerevisiae [55], C. elegans [56], D. melanogaster [56] and mice
consuming a high caloric diet [57]. The effects on life extension
appear to mimic several of the biochemical effects of calorie
restriction.
There is divergent evidence regarding the ability of resveratrol
to interact with sirtuin proteins. Sirtuins are NAD+-dependent
deacetylases that have been implicated to influence aging,
transcription regulation, apoptosis and stress resistance. The
deacetylase activity of sirtuins is directed to histone proteins and
transcription factors including p53, FOXO proteins and the
peroxisome proliferator activated receptor gamma (PPAR-c)
coactivator 1 alpha (PGC-1a) [58]. There are seven sirtuin genes
in humans (SIRT1-7). There is some debate regarding the ability of
resveratrol to directly activate Sirtuin 1 or increase expression of
the SIRT1 gene [53,55,59,60].
PGC-1a plays a role in the regulation of mitochondrial function
and fatty acid oxidation [61]. It is activated by deacetylation by
Sirtuin 1 which has also been shown to repress PPAR-c [62].
There is evidence of cross regulation mechanisms that act between
frataxin and PGC-1a. Reduced expression of PGC-1a has been
shown in FRDA cells, in several tissues of an FRDA mouse model
and upon inhibition of FXN gene expression by shRNA [63]. The
downregulation of PGC-1a by siRNA results in decreased FXN
transcript and frataxin protein in human control and FRDA
fibroblasts [64]. Conversely, the overexpression of PGC-1a in
skeletal muscle cells has been shown to increase frataxin levels
[65], and the PPAR-c agonist Azelaoyl PAF is able to increase
FXN gene expression and frataxin protein levels in FRDA cells
[66]. These findings suggest a mechanism that accounts for the
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observed increased levels of FXN gene expression and frataxin
protein levels mediated by resveratrol. It can be hypothesized that
the activation of Sirtuin 1 by resveratrol enables it to modulate the
activity of the PPAR-c and PGC-1a pathway which in turn
influences the regulation of FXN gene expression.
Resveratrol has a good safety profile and has not been reported
to have any major adverse side-effects in humans [67]. Of the
pharmacological compounds that we identified to increase FXN
gene expression, resveratrol had the most favorable safety criteria
for human use and is expected to be well tolerated by individuals
with FRDA. It is also able to cross the blood-brain barrier [68,69].
Pharmacokinetic studies indicate that the metabolization of
resveratrol into conjugated forms may influence its bioavailability
in higher organisms [70,71]. We therefore further evaluated
resveratrol pre-clinically in the YG8R humanized mouse model of
FRDA that contains the entire human FXN gene incorporating a
GAA trinucleotide repeat expansion. At a dose of 200 mg/kg
resveratrol was shown to increase human FXN gene transcription
by almost 2-fold and frataxin protein was found to increase by 1.5-
fold in transgenic mouse brain. It is curious that this was the only
dose at which FXN mRNA and frataxin protein were increased.
On the basis of this data, an open-label, proof of principle study of
resveratrol in individuals with FRDA is currently underway.
In conclusion, we have demonstrated the utility of using an
FXN-EGFP cellular genomic reporter assay in HTS procedures for
the identification of pharmacological compounds able to increase
FXN gene expression and frataxin protein. Any compound that
specifically increases frataxin levels by several-fold in individuals
with FRDA could serve as a potential pharmacological therapy for
the disorder. Candidate agents were processed along the drug
development pipeline from drug screening to lead identification
and resveratrol was selected for evaluation in pre-clinical animal
testing and is currently being evaluated in a human therapeutic
trial. Ultimately, a cocktail of drugs may be required to provide an
effective therapy for FRDA. This may include pharmacological
agents that address the primary defect of frataxin deficiency by
increasing FXN gene expression and/or frataxin protein such as
those identified in this study, HDAC inhibitors [72–74], erythro-
poietin [75–77], PPAR-c agonists [66] or IFNc [78], and those
directed at secondary effects, such as antioxidants and iron-
chelators.
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